Steatohepatitis, Nonalcoholic study: Hydrochloroquine
Official title Using Hydroxychloroquine (HCQ) to Treat Steatohepatitis
ClinicalTrials.gov ID: NCT07265297
What this study is testing
What is Hydrochloroquine?
An investigational oral tablet being studied as a potential treatment for non‑alcoholic steatohepatitis. Hydroxychloroquine is designed to modulate the immune system and reduce inflammation in the liver.
Also referred to as hydroxychloroquine.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to find out if hydroxychloroquine can improve steatohepatitis and whether it is safe to use.
- Who it's for
- Adults who have non‑alcoholic steatohepatitis.
- What's involved
- Participants will take hydroxychloroquine (either 200 mg or 400 mg) or a placebo every day for a year and have clinic visits every three months for check‑ups and tests.
- Time commitment
- The trial lasts 12 months with clinic visits once every three months.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Participants must be at least 18 years old.
- Participants must be able to return for scheduled follow-up visits during specific time points within the 12-month study period.
- Diagnosis of fatty liver confirmed by abdominal ultrasound or magnetic resonance imaging (MRI).
- Evidence of hepatic inflammation for more than three months, indicated by alanine aminotransferase (ALT) \> 41 IU/L.
You likely can't join if
- Participants younger than 18 years old.
- Pregnant or breastfeeding women.
- Active viral hepatitis, determined by serum HBV or HCV viral load.
- Currently taking hydroxychloroquine (HCQ) for other medical conditions or indications.
- Known history of hypersensitivity or severe adverse drug reaction to HCQ.
- Presence of retinal maculopathy.
The study team makes the final eligibility decision.
Where it is enrolling
- Taipei, Taiwan, Taiwan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Taipei, Taiwan, Taiwan. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.